DOCSLIB.ORG

Original Article GRK6 Over-Expression Predicts Poor Outcomes in Patients with Lung Adenocarcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Original Article GRK6 Over-Expression Predicts Poor Outcomes in Patients with Lung Adenocarcinoma Int J Clin Exp Pathol 2016;9(1):159-164 www.ijcep.com /ISSN:1936-2625/IJCEP0017807 Original Article GRK6 over-expression predicts poor outcomes in patients with lung adenocarcinoma Yuanzhu Jiang1, Chao Wang2, Yang Zhao3, Hongchang Shen4 1Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, P. R. China; 2Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan, P. R. China; 3Institute of Oncology, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, P. R. China; 4Department of Oncology, Provincial Hospital Af- filiated to Shandong University, Shandong University, Jinan, P. R. China Received October 13, 2015; Accepted November 28, 2015; Epub January 1, 2016; Published January 15, 2016 Abstract: Objective is to investigate the expression and potential roles of G protein-coupled receptor kinase 6 (GRK6) in lung adenocarcinoma patients. Immunohistochemistry was performed to determine GRK6 expression in 196 lung adenocarcinoma samples. And the relationship between expression and clinicopathological features was analyzed. Lung adenocarcinoma patients with higher GRK6 expression had poor outcomes. And GRK6 high expression was associated with metastasis and relapse. GRK6 overexpression may be a significant independent prognostic factor of lung adenocarcinoma. Keywords: GRK6, lung adenocarcinoma, prognosis Introduction 2006 to 2008, and all samples were confirmed by pathological histological analysis (Table 1). It Lung adenocarcinoma is one of commonest included 89 T1, 90 T2, 10 T3 and 5 T4. 90 malignant tumors, whose pathogenesis is still patients have lymph nodes metastasis. And 11 not complete clear. And its morbidity is rising patients had distant organs metastasis. 128 year by year in the whole world. GRK6 is an patients were in I~II pathologic stage and the important protein kinase in human, and it par- others were in III to IV pathologic stage. 65 ticipate many pathological process of different patients had relapse or metastasis. Besides, kinds of disease [1, 2]. GRK6 belongs to the 109 patients have chemoradiotherapy history. seven-member G-protein coupled receptor Among these 195 samples 173 patients have kinase family [3] and it regulates diverse cellu- follow-up information. 100 of them were still lar functions ranging from metabolism to alive until January 2014. Other 73 patients growth. GRK6 can regulate the activity of the were dead. chemokine receptor by phosphorylation [4, 5]. GRK6 antibody from rabbits and β-actin anti- Previous research has reported that the lack of body from rats were from Santa Cruz Company, GRK6 can prevent cancer progression [6]. chemiluminescent solution was supplied by However, the expression in lung adenocarcino- CST company, SP kit was from Dako, and the ma has not been reported. This study is to other chemical reagent was analytical reagent explore the expression and the function of made in china. GRK6 in lung adenocarcinoma and to analyze the correlation between GRK6 expression and Immunohistochemistry the clinicopathological features. Paraffin-embedded tissue sections (3 mm) Materials and methods were subjected to immunohistochemistry. Ti- ssue sections were made and used to assess Patients and clinical data the difference in histology and GRK6 expres- sion. Sections were deparaffinised by xylene, A total of 195 lung adenocarcinoma samples rehydrated in graded concentrations of ethanol, were collected from patients admitted from and were pretreated in an autoclave at 121°C GRK6 over-expression predicts poor outcomes in patients with lung adenocarcinoma Table 1. Relationship between clinical pathologic features and GRK trations of ethanol, trans- expression in lung adenocarcinoma tissue parented and fixed by neu- High ex- Low ex- Pearson tral xylene balata. GRK6 Clinical pathologic feature N P pression pression Chi-square expression was observed T classification 6.001 0.112 and analyzed under light T1 89 42 47 microscope, and was pre- sented by positive cell T2 90 48 42 percentage. T3 10 8 2 T4 5 4 1 Statistical analysis N classification 0.002 0.965 N1 90 46 44 All statistical analyses N0 105 54 51 were carried out with M classification 4.351 0.037 SPSS 13.0 statistical soft- M1 11 9 2 ware. Chi-square test was used for GRK6 expression. M0 184 91 93 The survival rate acquired Pathologic stages 0.16 0.689 from follow-up visit was I~II 128 64 64 analyzed with Kaplan- III~IV 66 35 31 Meier survival curve and Differentiation degree 2.525 0.471 Single variable Log rank Moderate-well~well 18 7 11 test. All the tests were two Poorly-moderate~moderate 143 76 67 sides and statistical sig- Poorly 26 12 14 nificance was set at P< Undifferentiated 1 1 0 0.05. In addition, a multi- Relapse & metastasis 5.429 0.02 variate analysis was con- Yes 65 41 24 ducted using the Cox pro- No 130 59 71 portional hazard model. Treatment history 3.578 0.059 Results Have chemoradiotherapy 109 61 48 No chemoradiotherapy 48 19 29 GRK6 expression in lung Alive or Death 7.193 0.007 adenocarcinoma and rela- Alive 100 41 59 tionship between GRK6 Death 73 45 28 and patients clinical characteristics for 15 min in 10 mM citrate buffer (pH 6.0). Relationship between clinical pathologic fea- Endogenous peroxidase activity was blocked by tures and GRK expression in lung adenocarci- incubation for 30 min with 0.3% hydrogen per- noma tissue was shown in Table 1. The expres- oxide in methanol. Non-specific binding sites sion of GRK6 in lung adenocarcinoma was were blocked in phosphate-buffered saline shown in Figure 1. According to the Chi-square (PBS, pH 7.4) with 10% normal rabbit serum. test, immunohistochemical result shows that The sections were then incubated with primary the high expression of GRK6 is associated with rabbit monoclonal antibody against GRK6 poor prognosis (P=0.007). It has statistic sig- (1:50) for a night at 4°C. Rewarming in the 37°C nificance between GRK6 expression and dis- caloratat for 30 minutes. After washing with tant organs metastasis (P=0.037). Besides, PBS, sections were loaded with secondary anti- the expression of GRK6 is associated with body (50l) for 30 min in the 37°C caloratat. relapse and distant metastasis (P=0.02). Then the sections were incubated with Streptomycin avidin-peroxide polymerase for Univariate analysis of clinical and pathologic 30 min in the 37°C caloratat. After washing characteristics with PBS, drop 100l DAB to get color. The sec- tions were counterstained with haematoxylin The univariate analysis of clinic and pathologic for 1-2 minutes, dehydrated in graded concen- characteristics was summarized in Table 2. 160 Int J Clin Exp Pathol 2016;9(1):159-164 GRK6 over-expression predicts poor outcomes in patients with lung adenocarcinoma Figure 1. A. The expression of GRK6 is positive at ×100 magnification (10× objective lens). B. The expression of GRK6 is negative at ×100 magnification (10× objective lens). C. The expression of GRK6 is positive at ×400 mag- nification (40× objective lens). D. The expression of GRK6 is negative at ×400 magnification (40× objective lens). Survival data of 173 cases was collected from stages (Hazard Ratio, HR=0.438, P=0.002) 195 cases, including 86 patients with high and GRK6 expression (HR=0.526, P=0.016) GRK6 expression and 87 patients with low showed statistic significance. This result indi- GRK6 expression. 5-year overall survival rate of cated that the expression of GRK6 might be an high GRK6 expression was 50%. And the low independent prognostic factor of lung adeno- GRK6 expression group was 68%. According to carcinoma. On the other hand, the chemoradio- the statistic analysis, the GRK6 expression therapy treatment history did not have statistic (P=0.011), chemoradiotherapy treatment (P= significance (HR=0.673, P=0.287). 0.002), TNM classification (P<0.001), patho- logic stages (P<0.001) and differentiation de- Discussion gree (P<0.001) were associated with outcome. And the Kaplan-Meier survival curve of GRK6 Lung adenocarcinoma has high malignant de- expression was shown in Figure 2 (P=0.011). gree and morbidity, whose postoperative recur- rence and metastasis are the significant fac- Multivariate analysis of clinical and pathologic tors of prognosis. Many cases fail to be diag- characteristics nosed until the late stage and losing the chance to be treated. It is urgent to find a significant The multivariate analysis of clinic and patho- target to help diagnose and therapy in the early logic characteristics was summarized in Table stage. The exploration of the metastasis is the 3. Using the Cox proportional hazard model, we pre-requisite way to go. While the metastasis of analysis the features that showed statistic sig- the lung adenocarcinoma is a multiple and nificance in univariate analysis. The pathologic complex stage process, the cancer cells abate 161 Int J Clin Exp Pathol 2016;9(1):159-164 GRK6 over-expression predicts poor outcomes in patients with lung adenocarcinoma Table 2. Survival Analysis--Univariate Analysis of Clinical signal transduction is blocked [9]. How- and Pathologic Characteristics ever, emerging evidence shows that the Features n 5-Year OS (%) P substrates of GRKs are far beyond the GPCRs. GRK can also combine with other T classification <0.001 kinds of receptors, such as Transforming T1 81 67 growth factor receptor (TGFR), Epidermal T2 77 57 growth factor receptor (EGFR), Platelet- T3 9 11 derived growth factor receptor (PDGFR), T4 5 60 Insulin-like growth factor receptor (IGFR) N classification <0.001 and so on [10]. The member of GRKs N1 83 41 contains a high conserved regulator of G N0 90 76 protein signaling protein domain, a Ser- M classification <0.001 Thr kinase domain which is similar to AGC M1 10 10 protein kinase domain, and a carboxyl terminal which is affected with cell mem- M0 163 62 brane [11].
Load more

Recommended publications
  • Defective Lymphocyte Chemotaxis in Я-Arrestin2- and GRK6-Deficient Mice
    Defective lymphocyte chemotaxis in ␤-arrestin2- and GRK6-deficient mice Alan M. Fong*, Richard T. Premont*, Ricardo M. Richardson*, Yen-Rei A. Yu†, Robert J. Lefkowitz*‡§, and Dhavalkumar D. Patel*†¶ Departments of *Medicine, ‡Biochemistry, and †Immunology, and §Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710 Contributed by Robert J. Lefkowitz, April 4, 2002 Lymphocyte chemotaxis is a complex process by which cells move kinase, extracellular receptor kinase, and c-jun terminal kinase within tissues and across barriers such as vascular endothelium and activation (9–12), they might also act as positive regulators of is usually stimulated by chemokines such as stromal cell-derived chemotaxis. To evaluate the role of the GRK-arrestin pathway factor-1 (CXCL12) acting via G protein-coupled receptors. Because in chemotaxis, we studied the chemotactic responses of lym- members of this receptor family are regulated (‘‘desensitized’’) by phocytes from ␤-arrestin- and GRK-deficient mice toward G protein-coupled receptor kinase (GRK)-mediated receptor phos- gradients of stromal cell-derived factor 1 (CXCL12), a well ␤ phorylation and -arrestin binding, we examined signaling and characterized chemokine whose receptor is CXCR4, a core- chemotactic responses in splenocytes derived from knockout mice ceptor for HIV. deficient in various ␤-arrestins and GRKs, with the expectation that these responses might be enhanced. Knockouts of ␤-arrestin2, Materials and Methods GRK5, and GRK6 were examined because all three proteins are :expressed at high levels in purified mouse CD3؉ T and B220؉ B Mice. The following mouse strains were used in this study splenocytes. CXCL12 stimulation of membrane GTPase activity was ␤-arrestin2-deficient (back-crossed for six generations onto the unaffected in splenocytes derived from GRK5-deficient mice but C57͞BL6 background; ref.
    [Show full text]
  • Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA–Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration
    Published OnlineFirst April 7, 2009; DOI: 10.1158/0008-5472.CAN-08-2515 Published Online First on April 7, 2009 as 10.1158/0008-5472.CAN-08-2515 Research Article Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA–Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration Yanling Chen,1 Bingwen Lu,2 Qingkai Yang,1 Colleen Fearns,3 John R. Yates III,2 and Jiing-Dwan Lee1 Departments of 1Immunology, 2Chemical Physiology, and 3Chemistry, The Scripps Research Institute, La Jolla, California Abstract cytoskeletal components (2, 7) and regulation of cell survival, Integrins interact with extracellular matrix (ECM) and deliver proliferation, differentiation, cell cycle, and migration (8, 9). Understanding the mechanism by which integrins modulate these intracellular signaling for cell proliferation, survival, and motility. During tumor metastasis, integrin-mediated cell cellular activities is of significant biological importance. adhesion to and migration on the ECM proteins are required The most common cancers in human include breast cancer, for cancer cell survival and adaptation to the new microen- prostate cancer, lung cancer, colon cancer, and ovarian cancer (10, 11), and their metastasis is the leading cause of mortality in vironment. Using stable isotope labeling by amino acids in cell cancer patients, causing 90% of deaths from solid tumors (11, 12). culture–mass spectrometry, we profiled the phosphoproteo- During the process of metastasis, tumor cells leave the primary mic changes induced by the interactions of cell integrins with site, travel via blood and/or lymphatic circulatory systems, attach type I collagen, the most common ECM substratum. Integrin- to the substratum of ECM at a distant site, and establish a ECM interactions modulate phosphorylation of 517 serine, secondary tumor, accompanied by angiogenesis of the newly threonine, or tyrosine residues in 513 peptides, corresponding formed neoplasm (12).
    [Show full text]
  • Investigating the Role of Cdk11in Animal Cytokinesis
    Investigating the Role of CDK11 in Animal Cytokinesis by Thomas Clifford Panagiotou A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Molecular Genetics University of Toronto © Copyright by Thomas Clifford Panagiotou (2020) Investigating the Role of CDK11 in Animal Cytokinesis Thomas Clifford Panagiotou Master of Science Department of Molecular Genetics University of Toronto 2020 Abstract Finely tuned spatio-temporal regulation of cell division is required for genome stability. Cytokinesis constitutes the final stages of cell division, from chromosome segregation to the physical separation of cells, abscission. Abscission is tightly regulated to ensure it occurs after earlier cytokinetic events, like the maturation of the stem body, the regulatory platform for abscission. Active Aurora B kinase enforces the abscission checkpoint, which blocks abscission until chromosomes have been cleared from the cytokinetic machinery. Currently, it is unclear how this checkpoint is overcome. Here, I demonstrate that the cyclin-dependent kinase CDK11 is required for cytokinesis. Both inhibition and depletion of CDK11 block abscission. Furthermore, the mitosis-specific CDK11p58 kinase localizes to the stem body, where its kinase activity rescues the defects of CDK11 depletion and inhibition. These results suggest a model whereby CDK11p58 antagonizes Aurora B kinase to overcome the abscission checkpoint to allow for successful completion of cytokinesis. ii Acknowledgments I am very grateful for the support of my family and friends throughout my studies. I would also like to express my deep gratitude to Wilde Lab members, both past and present, for their advice and collaboration. In particular, I am very grateful to Matthew Renshaw, whose work comprises part of this thesis.
    [Show full text]
  • The Emerging Roles and Therapeutic Potential of Cyclin- Dependent Kinase 11 (CDK11) in Human Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 26 Review The emerging roles and therapeutic potential of cyclin- dependent kinase 11 (CDK11) in human cancer Yubing Zhou1,2, Jacson K. Shen2, Francis J. Hornicek2, Quancheng Kan1 and Zhenfeng Duan1,2 1 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China 2 Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America Correspondence to: Quancheng Kan, email: [email protected] Correspondence to: Zhenfeng Duan, email: [email protected] Keywords: CDK11, CDKs inhibitor, cell cycle, therapeutic target, cancer therapy Received: January 20, 2016 Accepted: March 28, 2016 Published: March 31, 2016 ABSTRACT Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK family and recent studies have shown that CDK11 also plays critical roles in cancer cell growth and proliferation. A variety of genetic and epigenetic events may cause universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been shown to lead to cancer cell death and apoptosis. Significant evidence has suggested that CDK11 may be a novel and promising therapeutic target for the treatment of cancers. This review will focus on the emerging roles of CDK11 in human cancers, and provide a proof-of-principle for continued efforts toward targeting CDK11 for effective cancer treatment.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Targeting CDK2 Overcomes Melanoma Resistance Against BRAF and Hsp90 Inhibitors
    Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Downloaded from: https://research.chalmers.se, 2019-05-11 18:56 UTC Citation for the original published paper (version of record): Azimi, A., Caramuta, S., Seashore-Ludlow, B. et al (2018) Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Molecular Systems Biology, 14(3) http://dx.doi.org/10.15252/msb.20177858 N.B. When citing this work, cite the original published paper. research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology. It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004. research.chalmers.se is administrated and maintained by Chalmers Library (article starts on next page) Published online: March 5, 2018 Article Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Alireza Azimi1,†, Stefano Caramuta1,†, Brinton Seashore-Ludlow2,†, Johan Boström3 , Jonathan L Robinson4, Fredrik Edfors5, Rainer Tuominen1, Kristel Kemper6, Oscar Krijgsman6 , Daniel S Peeper6 , Jens Nielsen4 , Johan Hansson1, Suzanne Egyhazi Brage1, Mikael Altun3 , Mathias Uhlen5 & Gianluca Maddalo5,* Abstract Introduction Novel therapies are undergoing clinical trials, for example, the Malignant melanoma has the highest somatic mutational rate Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for among cancers (Alexandrov et al, 2013) and its incidence is steadily the treatment of therapy-resistant melanomas. Unfortunately, our increasing (https://training.seer.cancer.gov/melanoma/intro/). In data show that this combination elicits a heterogeneous response the majority of the cases, it harbors BRAF (~60%) or NRAS (~20%) in a panel of melanoma cell lines including PDX-derived models.
    [Show full text]
  • High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
    Supplementary Information High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype Håkon Reikvam 1,2,*, Elise Aasebø 1, Annette K. Brenner 2, Sushma Bartaula-Brevik 1, Ida Sofie Grønningsæter 2, Rakel Brendsdal Forthun 2, Randi Hovland 3,4 and Øystein Bruserud 1,2 1 Department of Clinical Science, University of Bergen, 5020, Bergen, Norway 2 Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway 3 Department of Medical Genetics, Haukeland University Hospital, 5021, Bergen, Norway 4 Institute of Biomedicine, University of Bergen, 5020, Bergen, Norway * Correspondence: [email protected]; Tel.: +55-97-50-00 J. Clin. Med. 2019, 8, x 2 of 36 Figure S1. Mutational studies in a cohort of 71 AML patients. The figure shows the number of patients with the various mutations (upper), the number of mutations in for each patient (middle) and the number of main classes with mutation(s) in each patient (lower). 2 J. Clin. Med. 2019, 8, x; doi: www.mdpi.com/journal/jcm J. Clin. Med. 2019, 8, x 3 of 36 Figure S2. The immunophenotype of primary human AML cells derived from 62 unselected patients. The expression of the eight differentiation markers CD13, CD14, CD15, CD33, CD34, CD45, CD117 and HLA-DR was investigated for 62 of the 71 patients included in our present study. We performed an unsupervised hierarchical cluster analysis and identified four patient main clusters/patient subsets. The mutational profile for each f the 62 patients is also given (middle), no individual mutation of main class of mutations showed any significant association with any of the for differentiation marker clusters (middle).
    [Show full text]
  • Selective Engagement of G Protein Coupled Receptor Kinases (Grks) Encodes Distinct Functions of Biased Ligands
    Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands David A. Zidara, Jonathan D. Violina, Erin J. Whalena, and Robert J. Lefkowitza,b,c,1 Departments of aMedicine, bBiochemistry, and cHoward Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710 Contributed by Robert J. Lefkowitz, April 24, 2009 (sent for review February 13, 2009) CCL19 and CCL21 are endogenous agonists for the seven-trans- to be uniquely required for ␤-arrestin-mediated MAP kinase membrane receptor CCR7. They are equally active in promoting G signaling (16, 17). protein stimulation and chemotaxis. Yet, we find that they result The chemokine receptor CCR7 is particularly important for in striking differences in activation of the G protein-coupled immune responses requiring the coordinated interaction of receptor kinase (GRK)/ß-arrestin system. CCL19 leads to robust various cell types within lymphoid tissues (18, 19). It is unique CCR7 phosphorylation and ␤-arrestin2 recruitment catalyzed by for its high expression on mature, naïve T lymphocytes and is both GRK3 and GRK6 whereas CCL21 activates GRK6 alone. This vital for homeostatic recirculation of these cells through sec- differential GRK activation leads to distinct functional conse- ondary lymphoid tissues. CCR7 has two endogenous ligands, quences. Although each ligand leads to ␤-arrestin2 recruitment, CCL19 and CCL21, which have evolved from a series of complex only CCL19 leads to redistribution of ␤-arrestin2-GFP into endocytic gene duplications and retain 32% amino acid sequence homol- vesicles and classical receptor desensitization. In contrast, these ago- ogy (20–22). They are predicted to be structurally similar except ␤ nists are both capable of signaling through GRK6 and -arrestin2 to that CCL21 has a conserved motif consisting of an additional 37 ERK kinases.
    [Show full text]
  • Detection of Selection Signatures in Farmed Coho Salmon (Oncorhynchus Kisutch) Using Dense Genome‑Wide Information M
    www.nature.com/scientificreports OPEN Detection of selection signatures in farmed coho salmon (Oncorhynchus kisutch) using dense genome‑wide information M. E. López1, M. I. Cádiz2, E. B. Rondeau3, B. F. Koop3 & J. M. Yáñez2,4* Animal domestication and artifcial selection give rise to gradual changes at the genomic level in populations. Subsequent footprints of selection, known as selection signatures or selective sweeps, have been traced in the genomes of many animal livestock species by exploiting variation in linkage disequilibrium patterns and/or reduction of genetic diversity. Domestication of most aquatic species is recent in comparison with land animals, and salmonids are one of the most important fsh species in aquaculture. Coho salmon (Oncorhynchus kisutch), cultivated primarily in Chile, has been subjected to breeding programs to improve growth, disease resistance traits, and fesh color. This study aimed to identify selection signatures that may be involved in adaptation to culture conditions and traits of productive interest. To do so, individuals of two domestic populations cultured in Chile were genotyped with 200 thousand SNPs, and analyses were conducted using iHS, XP‑EHH and CLR. Several signatures of selection on diferent chromosomal regions were detected across both populations. Some of the identifed regions under selection contained genes such anapc2, alad, chp2 and myn, which have been previously associated with body weight in Atlantic salmon, or sec24d and robo1, which have been associated with resistance to Piscirickettsia salmonis in coho salmon. Findings in our study can contribute to an integrated genome‑wide map of selection signatures, to help identify the genetic mechanisms of phenotypic diversity in coho salmon.
    [Show full text]
  • Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy*□S
    crossmark Research Author’s Choice © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy*□S Rolf Turk‡§¶ʈ**, Jordy J. Hsiao¶, Melinda M. Smits¶, Brandon H. Ng¶, Tyler C. Pospisil‡§¶ʈ**, Kayla S. Jones‡§¶ʈ**, Kevin P. Campbell‡§¶ʈ**, and Michael E. Wright¶‡‡ Mutations in genes encoding components of the sar- The muscular dystrophies are hereditary diseases charac- colemmal dystrophin-glycoprotein complex (DGC) are re- terized primarily by the progressive degeneration and weak- sponsible for a large number of muscular dystrophies. As ness of skeletal muscle. Most are caused by deficiencies in such, molecular dissection of the DGC is expected to both proteins associated with the cell membrane (i.e. the sarco- reveal pathological mechanisms, and provides a biologi- lemma in skeletal muscle), and typical features include insta- cal framework for validating new DGC components. Es- bility of the sarcolemma and consequent death of the myofi- tablishment of the molecular composition of plasma- ber (1). membrane protein complexes has been hampered by a One class of muscular dystrophies is caused by mutations lack of suitable biochemical approaches. Here we present in genes that encode components of the sarcolemmal dys- an analytical workflow based upon the principles of pro- tein correlation profiling that has enabled us to model the trophin-glycoprotein complex (DGC). In differentiated skeletal molecular composition of the DGC in mouse skeletal mus- muscle, this structure links the extracellular matrix to the cle. We also report our analysis of protein complexes in intracellular cytoskeleton.
    [Show full text]
  • The Mitotic Checkpoint Is a Targetable Vulnerability of Carboplatin-Resistant
    www.nature.com/scientificreports OPEN The mitotic checkpoint is a targetable vulnerability of carboplatin‑resistant triple negative breast cancers Stijn Moens1,2, Peihua Zhao1,2, Maria Francesca Baietti1,2, Oliviero Marinelli2,3, Delphi Van Haver4,5,6, Francis Impens4,5,6, Giuseppe Floris7,8, Elisabetta Marangoni9, Patrick Neven2,10, Daniela Annibali2,11,13, Anna A. Sablina1,2,13 & Frédéric Amant2,10,12,13* Triple‑negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking efective therapy. Many TNBCs show remarkable response to carboplatin‑based chemotherapy, but often develop resistance over time. With increasing use of carboplatin in the clinic, there is a pressing need to identify vulnerabilities of carboplatin‑resistant tumors. In this study, we generated carboplatin‑resistant TNBC MDA‑MB‑468 cell line and patient derived TNBC xenograft models. Mass spectrometry‑based proteome profling demonstrated that carboplatin resistance in TNBC is linked to drastic metabolism rewiring and upregulation of anti‑oxidative response that supports cell replication by maintaining low levels of DNA damage in the presence of carboplatin. Carboplatin‑ resistant cells also exhibited dysregulation of the mitotic checkpoint. A kinome shRNA screen revealed that carboplatin‑resistant cells are vulnerable to the depletion of the mitotic checkpoint regulators, whereas the checkpoint kinases CHEK1 and WEE1 are indispensable for the survival of carboplatin‑ resistant cells in the presence of carboplatin. We confrmed that pharmacological inhibition of CHEK1 by prexasertib in the presence of carboplatin is well tolerated by mice and suppresses the growth of carboplatin‑resistant TNBC xenografts. Thus, abrogation of the mitotic checkpoint by CHEK1 inhibition re‑sensitizes carboplatin‑resistant TNBCs to carboplatin and represents a potential strategy for the treatment of carboplatin‑resistant TNBCs.
    [Show full text]
  • Adrenergic Receptor Transactivation of the EGFR Confers Cardioprotection
    β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection Takahisa Noma, … , Robert J. Lefkowitz, Howard A. Rockman J Clin Invest. 2007;117(9):2445-2458. https://doi.org/10.1172/JCI31901. Research Article Deleterious effects on the heart from chronic stimulation of β-adrenergic receptors (βARs), members of the 7 transmembrane receptor family, have classically been shown to result from Gs-dependent adenylyl cyclase activation. Here, we identify a new signaling mechanism using both in vitro and in vivo systems whereby β-arrestins mediate β1AR signaling to the EGFR. This β-arrestin–dependent transactivation of the EGFR, which is independent of G protein activation, requires the G protein–coupled receptor kinases 5 and 6. In mice undergoing chronic sympathetic stimulation, this novel signaling pathway is shown to promote activation of cardioprotective pathways that counteract the effects of catecholamine toxicity. These findings suggest that drugs that act as classical antagonists for G protein signaling, but also stimulate signaling via β-arrestin–mediated cytoprotective pathways, would represent a novel class of agents that could be developed for multiple members of the 7 transmembrane receptor family. Find the latest version: https://jci.me/31901/pdf Related Commentary, page 2396 Research article β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection Takahisa Noma,1 Anthony Lemaire,1 Sathyamangla V. Naga Prasad,1 Liza Barki-Harrington,1 Douglas G. Tilley,1 Juhsien Chen,1 Philippe Le Corvoisier,1 Jonathan D. Violin,1 Huijun Wei,1 Robert J. Lefkowitz,1,2 and Howard A. Rockman1,3,4 1Department of Medicine, 2Howard Hughes Medical Institute, 3Department of Cell Biology, and 4Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA.
    [Show full text]